CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients

Bayer

Status: Completed

Conditions: Pneumonia

Treatments: Drug: Moxifloxacin (Avelox, BAY12-8039)

Study type: Observational

Funder types: Industry

Identifiers

NCT00987792

14522

AX0801 (Other Identifier)

Details and patient eligibility

About

The aim of this study is to obtain data from hospitalized Community Acquired Pneumonia (CAP) patients on the disease including disease severity, clinical signs and symptoms and measures used for diagnosis in daily routine practice as well as data on Avelox® including information on the use, effectiveness, treatment outcome, safety and tolerability.

As this is a non-interventional observational study, routine clinical practice is observed. The application of medications follows the normal routines and is decided by the treating physician under recognition of the package insert.

Enrollment: 2,595 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult hospitalized patients with a diagnosis of CAP (based on local medical practice) and decision taken by the investigator to treat with moxifloxacin and to start treatment with intravenous administration. The local moxifloxacin product information must be considered.

Exclusion criteria

• Contraindications stated in the local moxifloxacin product information; warnings and precautions must be considered.

Trial design

2,595 participants in 1 patient group

Group 1

Treatment:

Drug: Moxifloxacin (Avelox, BAY12-8039)